SB1555 creates a conditional Arizona controlled-substances framework for a future FDA-approved psilocybin medication. The bill adds a new statute providing that any pharmaceutical composition of crystalline polymorph psilocybin that is approved by the U.S. Food and Drug Administration and rescheduled by the U.S. Drug Enforcement Administration to a schedule other than Schedule I would be treated as a controlled substance under Arizona law and could be prescribed in the state. The measure also states legislative intent that, if those federal approvals occur, patients should have rapid access to the treatment.
The bill does not legalize psilocybin generally. Instead, it anticipates a narrow, prescription-only medical product and ties Arizona’s treatment of that product to federal approval and rescheduling. It also amends Arizona’s controlled-substances nomenclature provisions so the new category is incorporated into the state schedules if the conditions are met. The bill includes a sunset-like conditional structure: the changes only take effect if crystalline polymorph psilocybin is newly approved as a prescription medication and federally controlled under an interim final rule by January 1, 2031, and the Arizona State Board of Pharmacy must notify legislative leadership by February 1, 2031 whether the condition occurred.
Impact
SB1555 amends Arizona Revised Statutes Title 36, chapter 27, article 2, by adding section 36-2517.02 and updating section 36-2511 to reference that new section. Its practical effect is to pre-authorize state-law treatment of a specific psilocybin-based medication if and when federal regulators approve and reschedule it, allowing it to be prescribed in Arizona without further state legislation. The bill’s impact is therefore contingent and limited to a future FDA-approved, DEA-rescheduled pharmaceutical product, rather than broader psilocybin services or general psychedelic use.
Sentiment
The bill appears to have received generally favorable treatment in both chambers, with strong committee and floor support overall. It passed the Senate 23-4 on third reading, the House 40-19 on third reading, and later the Senate concurrence vote 25-5, indicating majority support but not unanimity. The committee votes also show support, including a unanimous Senate Rules action and strong House committee approval, suggesting the measure was viewed as a targeted medical-access bill rather than a sweeping drug-policy change.
Contention
The main point of contention is the policy choice to create a state pathway for a psilocybin-derived medication tied to future federal approval, which likely raised concerns among members wary of expanding controlled-substance access. The narrowness of the bill may have reduced opposition: it applies only to a specific pharmaceutical composition, only if FDA approval and DEA rescheduling occur, and only if those events happen by 2031. Supporters likely emphasized patient access and rapid implementation for a potential treatment option, while opponents appear to have focused on controlled-substance policy and the appropriateness of preemptively aligning state law with a psychedelic medication.